At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 50 enrolled
Drug / intervention
Deferiprone +3 moredrug
Likely dose
Deferiprone 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Crossover, Thorough QT/QTc Trial to Evaluate the Potential of Deferiprone to Prolong the QT Interval in Healthy Subjects
In Brief
A Phase 4 clinical trial evaluating Deferiprone, deferiprone matching placebo tablets, and 2 other interventions for Prolonged QTc Interval. Completed, enrolled 50 participants across 1 site.
Detailed Summary
Randomized, single-dose, double-blind, placebo and active controlled, four-period crossover study to evaluate the effect of deferiprone on QTc prolongation after administration of a single therapeutic (33 mg/kg) and supratherapeutic(50 mg/kg) oral doses of deferiprone in healthy volunteers as compared to placebo treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProlonged QTc Interval
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2012
Primary CompletionDec 2012
First PostedMay 2013
Study CompletionJul 2013
TodayJul 2026
First PostedMay 23, 2013
Enrollment StartNov 1, 2012
Primary CompletionDec 1, 2012
Study CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 13.1 years ago
Interventions
Deferipronedrug
Ferriprox 500 mg tablets
deferiprone matching placebo tabletsdrug
deferiprone matching placebo tablets
moxifloxacindrug
Active control
placebodrug
moxifloxacin-matching placebo